Table 2.

Summary of the published studies on open surgery and EVAR for aneurysmal lesions in patients with BD.

First author	Published year	Total no. of cases	Involvement	Number of open heart surgeries	Number of EVAR procedures	Number of aneurysm-related deaths	Number of recurrences	Systemic immunosuppressive medication	Follow-up (months)
Kwon	2008	12	Abdominal aortic aneurysm	21	0	1 / 12(rupture of recurrent aneurysm)	8//21 (38.1%)	Only postoperative medication (steroids, colchicine, azathioprine, or cyclophosphamide)was administered to all patients	45.4
Tuzun	2012	25	Peripheral arterial aneurysm	22	0	1/22(anastomotic dehiscence)	5/22 (22.7%)	Immunosuppression with cyclophosphamideand corticosteroids before intervention and continued post-operatively	88.8
Yang	2013	21	Peripheral arterial lesions	24	10	1/21(leakage after EVAR and consequent rupture of pseudoaneurysm)	10/21 (47.6%)	Combination of medications including azathioprine, steroids and colchicine before intervention except in 10 patients who had been referred from other institutes	78.7
Park	2001	7	Peripheral arterial aneurysm	0	9	0	1/7 (14.3%)	Not described.	28
Kwon	2003	9	Arterial pseudoaneurysm	0	11	0	1/9 (11.1%)	Immunosuppressive agents (azathioprine,prednisolone) before and after the procedure except in 1 patient with a delayed diagnosis	24.1
Kim WH	2009	34	Non-cerebral arterial aneurysm	7	16	1/23(aneurysm-related death after EVAR)	4/23 (17.4%)	Prednisolone 60 mg/d before intervention to induce remission	47.6
Liu	2009	10	Aortic pseudoaneurysm	0	10	1/10(rupture of recurrent pseudoaneurysm)	2/10 (20%)	All patients received immunosuppressive therapy before and after intervention	21.5
Kim SW	2014	10	Aortic pseudoaneurysm	0	10	0	1/10 (10%)	Immunosuppressivetherapy at the time of EVAR and continued during follow-up except in 1 patient	57